Phaco advance minimizes risk of endothelial cell loss

June 1, 2002

Rockville Centre, NY-Sonolase, a new mode of phacoemulsification power produced by the WhiteStar software for the Sovereign system (Advanced Medical Optics Inc. [AMO], the new entity formed in the recent Allergan spin-off), reduces the amount of energy expended in the eye and minimizes corneal endothelial cell loss.